Increased risk of invasive breast cancer observed in postmenopausal women using conjugated equine estrogens in combination with medroxyprogesterone acetate. An increase in abnormal mammograms also reported with estrogen and progestin therapy. Progesterone might cause transient dizziness or drowsiness during initial therapy. Risk of dementia may be increased in postmenopausal women. Pending examination should be discontinued in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine. Progestins used in combination with estrogen should not be used to prevent coronary heart disease (use caution with cardiovascular disease or dysfunction). Progestins used in combination with estrogen may increase risks of hypertension, myocardial infarction, stroke, pulmonary emboli, and deep vein thrombosis. Use with caution in history of depression, and in diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or renal dysfunction. Not for use prior to menarche. Whenever possible, progestins in combination with estrogens should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with increased risk of thromboembolism or during periods of prolonged immobilization. Some products may contain benzyl alcohol, palm oil, peanut oil, or sesame oil.